WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009137827) CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/137827    International Application No.:    PCT/US2009/043435
Publication Date: 12.11.2009 International Filing Date: 11.05.2009
IPC:
A01N 37/12 (2006.01)
Applicants: TIARA PHARMACEUTICALS, INC. [US/US]; 181 Leota Ave Sunnyvale, CA 94086-7031 (US) (For All Designated States Except US).
ARAD, Yadon [US/US]; (US) (For US Only).
DONG, Liang, C. [US/US]; (US) (For US Only)
Inventors: ARAD, Yadon; (US).
DONG, Liang, C.; (US)
Agent: LU, Yong; Cooley LLP 777 6th Street, NW Suite 1100 Washington, DC 20001 (US)
Priority Data:
61/052,120 09.05.2008 US
61/143,105 07.01.2009 US
Title (EN) CONTROLLED RELEASE OF N-ACETYLCYSTEINE (NAC) FOR REDUCTION OF SYSTEMIC AND/OR VASCULAR INFLAMMATION
(FR) LIBÉRATION CONTRÔLÉE DE N-ACÉTYLCYSTÉINE (NAC) EN VUE DE LA RÉDUCTION DE L'INFLAMMATION SYSTÉMIQUE ET/OU VASCULAIRE
Abstract: front page image
(EN)The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.
(FR)La présente invention concerne une composition à libération contrôlée assurant une concentration plasmatique, efficace d'un point de vue thérapeutique, en N-acétylcystéine sur une durée prolongée. La présente invention concerne également l'utilisation de ladite composition à libération prolongée, soit seule soit en combinaison avec au moins un principe actif supplémentaire, en vue d'une diminution de la concentration en marqueur de l'inflammation vasculaire et en vue du traitement de maladies, affections et/ou symptômes associés à l'inflammation systémique et/ou vasculaire chez un patient. En outre, la présente invention concerne un procédé de fabrication de granulés comprenant de la N-acétylcystéine, ou un sel, un solvate, un promédicament et/ou un analogue de celle-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)